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Abstract
Background: Loss of CBX7 expression has been described in several malignant neoplasias, including human colon
and thyroid carcinomas proposing CBX7 as a tumor suppressor gene with a key role in cancer progression. This role
is supported from the development of benign and malignant neoplasias in Cbx7 null mice.
The aim of our work has been to investigate the mechanisms underlying the CBX7 oncosuppressor activity by
analyzing the microRNAs (miRNAs) regulated by CBX7.
Methods: The miRNA expression profiles of the mouse embryonic fibroblasts (MEFs) null for Cbx7 and the wild-type
counterpart were analyzed by the miRNACHIP microarray and then validated by qRT-PCR. To asses KRAS as target of
miR-155 we evaluated the protein levels after transfection of the synthetic miR-155. Human colon carcinoma samples
have been investigated for the expression of CBX7 and miR-155.
Results: Twenty miRNAs were found upregulated and nine, including miR-155, downregulated in cbx7-null MEFS in
comparison with the wild-type ones. Then, we focused on miR-155 since several studies have shown its deregulated
expression in several human malignancies and, moreover, was the most downregulated miRNA. Subsequently, we
searched for miR-155 target genes demonstrating that KRAS protein levels are directly modulated by miR-155. A direct
significant correlation (r = 0.6779) between CBX7 and miR-155 expression levels was found in a set of human colon
carcinoma tissue samples.
Conclusion: miR-155 is positively regulated by CBX7 in MEFs and colon carcinomas, and has KRAS as one of the target
genes likely accounting for the anti-apoptotic activity ascribed to miR-155 in some tissue contexts.
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Background
CBX7 belongs to the polycomb repressive complex 1
(PRC1), a multiprotein complex that together with the
polycomb repressive complex 2 (PRC2) inhibits the tran-
scription of the developmental genes [1–3]. A crucial ac-
tivity of CBX7 in tumor progression is supported by
several studies [4]. Indeed, a drastic downregulation of
CBX7 expression has been described in thyroid [5], pan-
creatic [6], colon [7], lung [8], gastric [9], bladder [10],
breast [11] carcinomas, and a more advanced stage of
neoplastic disease and a poor survival has been directly
correlated to the loss of CBX7 expression [6, 7]. Further-
more, when CBX7 expression is restored in thyroid [5],
gastric [9] and colon [7] carcinoma cells there is a de-
creased proliferation rate with the accumulation of the
cells in the G1 phase of the cell cycle, suggesting a nega-
tive role of CBX7 on the control of cell growth and,
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particularly, in the regulation of the G1/S switch of the
cell cycle [5].
CBX7 is able to interact with different proteins, modu-
lating in positive or negative the expression of several
genes implicated in various biological functions [4]. In
particular, it positively regulates the expression of E-
cadherin [12] that is required to maintain the regular
morphology of epithelial cell, and whose loss of expres-
sion is associated with the epithelial-mesenchymal tran-
sition [13, 14]. The CBX7 activation of E-cadherin
expression is caused by the interaction with histone dea-
cetylase 2 and inhibition of its action on the CDH1 pro-
moter [12]. Consistently, two studies, in thyroid [12] and
pancreatic [6] carcinomas, report a direct correlation be-
tween the CBX7 expression and the E-cadherin levels.
Moreover, we have also shown that CBX7 counteracts
the HMGA-induced activation of the SPP1 gene [15],
encoding the chemokine osteopontin, that is highly over-
expressed in several human carcinomas and has a key
function in malignant transformation. Furthermore,
CBX7 inhibits, by a similar mechanism, the promoter
activity of Cyclin E gene [8], that enhances the transition
of the G1 to S phase of the cell cycle then increasing the
cell proliferation rate. Therefore, on the basis of all these
studies, the absence of the CBX7 gene expression plays
an important function in the late stages of human malig-
nancies [4].
MicroRNAs (miRNAs) have become known as a sig-
nificant class of short endogenous RNAs that control
gene expression at post-transcriptional level through
base-pairing with their target mRNAs for direct cleavage
or by inhibiting mRNA translation [16–18]. They have a
central function in a lot of biological pathways, as devel-
opmental process, signaling transduction, stem cell dif-
ferentiation, cell growth, and cancer [19, 20].
In the current study, we have carried out an analysis
of miRNA expression profiling in mouse embryonic fi-
broblasts (MEFs) obtained from Cbx7-knockout (KO)
and wild-type (WT) mice to search for the miRNAs
modulated by the Cbx7 protein. Among the differentially
expressed miRNAs in WT and Cbx7-null MEFs, we con-
centrated our attention on the miR-155, downregulated
in homozygous Cbx7-KO MEFs in comparison to the
WT. Consistently, we report downregulation of both
CBX7 and miR-155 expression in a set of colon carcin-




Primary MEFs from Cbx7+/+, Cbx7+/−, Cbx7−/− and
transgenic (TG) Cbx7 mice, were obtained and grown as
previously described [8].
Human embryonic kidney HEK 293 cells and lung
cancer cell lines A549 were cultured as reported else-
where [8, 21].
miRNACHIP microarray
RNA labeling, hybridization on miRNA microarray chips
and microarray analyses were carried out as reported
elsewhere [22, 23].
Briefly, 5 μg of total RNA from each sample were
biotin-labeled through reverse transcription by random
examers. Hybridization was performed on a miRNA
microarray chip [22] containing 368 probes in triplicate.
Hybridization signals were identified through biotin
binding of a streptavidin-alexa 647 conjugate by a
Perkin-Elmer ScanArray XL5K (Perkin-Elmer, Wellesley,
MA, USA) and quantified by the Quantarray software
(Perkin-Elmer). Raw data were normalized and analyzed
by GENESPRING software (Silicon Genetics, Redwood
City, CA, USA). miRNAs were quantified by class com-
parison using Student’s t test procedure. Each sample
was studied for miRNA expression profile in triplicate.
Bioinformatic prediction of miRNA target genes
Genes potentially targeted by the selected miRNAs were




RNA extraction, reverse transcription and quantitative
real time (qRT-PCR)
Total RNA was extracted from cells and tissue samples
using Trizol (Invitrogen, Carlsbad, CA), according to
manufacturer’s instructions. In particular, tissue samples
were dissociated with homogenizer. For mRNA detec-
tion, 1 mg of RNA from each sample was reverse-
transcribed using QuantiTech Reverse Transcription kit
(Qiagen, Valencia, CA) [24] and then Real-Time PCR
was performed by using iQ SybrGreen SuperMix
(BioRad, Hercules, CA). qRT-PCR analyses were per-
formed using the following primers:
h CBX7-fw 5’-cgagtatctggtgaagtggaaa-3’
h CBX7 rev 5’-gggggtccaagatgtgct-3’
h KRAS-fw 5’-aggctcaggacttagcaagaa-3’
h KRAS-rev 5’-gaaggcatcatcaacaccct-3’
m KRAS-fw 5’- tgtggatgagtatgaccctacg-3’
m KRAS-rev 5’- ccctcattgcactgtactcct-3’
For miRNA detection, RNA from each sample was
reverse-transcribed using miScript reverse transcription
Kit (Qiagen, Valencia, CA). Real-Time PCR was per-
formed according to miScript System Kits (Qiagen, Val-
encia, CA) instructions [24]. Real-Time PCR reactions
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contained miScript Primer Sets (Qiagen, Valencia, CA),
specific for mir-155 (5’-UUAAUGCUAAUCGUGAU
AGGGGU-3’) and U6 (cod. MS00033740) (used to
normalize RNA levels).
Plasmids and transfections
miRNA transfection were performed as described else-
where [23].
The KRAS 3’-UTR region, containing binding sites for
miR-155, was amplified by PCR using the primers KRAS
fw 5’-aatttctagaggcatactagtacaagtggt-3’ and KRAS rev 5’-
aatttctagacagggatgacaaactatagg-3’. The amplified frag-
ments were cloned as previously described [23]. Muta-
tion of miR155-binding site (acgtaaa) was synthesized
by IDT (TEMA ricerca, Bologna, Italy).
Protein extraction, western blotting, and antibodies
Protein extraction and Western blotting were performed
as previously described [8]. Primary antibodies used
were anti-KRAS (H00003845-M01, Abnova and sc-30,
Santa Cruz), anti-Actin (sc-1616, Santa Cruz) anti-
Gapdh (sc-32233, Santa Cruz). Western blotting detec-
tion reagents (Thermo Scientific, Rockville, IL) were
used to visualize immunoblots.
Dual-luciferase reporter assay
4 × 104 293 cells were co-transfected in 24-well dishes
with the pGL3-KRAS 3’-UTR luciferase reporter con-
struct or with the mutated KRAS 3’-UTR luciferase vec-
tor, together with the Renilla luciferase plasmid and with
the RNA oligonucleotides (Ambion), using lipofectamine
plus (Ambion). The pRL-TK control vector expressing
Renilla luciferase (Promega) was used to normalize cell
number and transfection efficiency. Luciferase activity
was measured as previously reported [25].
Collection and processing of surgical resections
Carcinoma and normal colon samples were obtained
from patients undergoing surgery for colorectal carcin-
oma (CRC) at two University Hospitals (Second Univer-
sity of Naples and University “Federico II”). Following
surgical resection of the bowel tract, a fragment of the
tumor and non-pathological tissue were collected from
the fresh specimen. Then, samples were divided into
several fragments for future extractions of nucleic acids
(DNA and RNA) and proteins. Fractionated tissue sam-
ples for extractions were then stored at -80 °C.
Statistical analysis
Statistical analyses were performed through using
GraphPad Prism. The comparison between two groups
of experiments was carried out using Student’s t test. Re-
sults are reported as means ± SD and differences were
considered to be significant with p < 0.05.
Results
MiRNA expression profile of MEFs isolated from Cbx7-
knockout (Cbx7 KO) mice
First, we analyzed by the miRNACHIP microarray [22]
the expression profile of miRNAs in MEFs deriving from
WT and Cbx7 KO mice to identify the miRNAs differen-
tially expressed in MEF null for Cbx7 in comparison
with the WT counterpart. Then, we applied biostatistical
analysis (see Methods section), acquiring a list of miR-
NAs that were differentially expressed (P < 0.05) between
WT and homozygous Cbx7 KO MEFs (Tables 1 and 2).
The next step was to validate the data acquired by
microarray Chip, analyzing 5 deregulated miRNAs by
qRT-PCR. The results presented in Fig. 1 confirm a
drastic overexpression of miR-181, miR-137, miR-199,
miR-706 and miR-719 and repression of miR-155 in
Cbx7 KO MEFs in comparison with the WT ones.
Then, we focused on the miR-155, which revealed the
most decreased fold-change in Cbx7-null MEFs (Table 1).
Moreover, its expression has been frequently found
deregulated in human malignancies [26, 27], and its
oncogenic activity has been described also in vivo [28].
We then extended the analysis of miR 155 expression,
by qRT-PCR, also to MEFs overexpressing Cbx7 [8] and
other Cbx7 KO MEF preparations. As presented in the
Fig. 2a and b, miR-155 levels decrease in KO MEFs in
comparison with the WT ones and it was upregulated in
those overexpressing Cbx7.
KRAS oncogene is target of miR-155
To identify possible mRNA targets of the CBX7-regulated
miRNAs, we referred to different on-line available bio-
informatic tools (see Methods). Among the numerous po-
tential targets of the miR-155, we focused on KRAS
because of its key role in development and cancer. Indeed,
mutations in the KRAS gene have been recurrently un-
veiled in numerous neoplasias comprising lung, pancreatic
and colon carcinomas [29–31], where we have previously
found a significant downregulation of CBX7 expression.
Moreover, it has also been reported an increased KRAS
expression in human colon carcinomas [32].
In Fig. 3 Panel a, we show that 3’UTR of KRAS has
one putative binding site for the miR-155. Then, to con-
firm the effect of the miR-155 on the selected candidate
target, we evaluated KRAS protein levels in 293 cells
transfected with the miR-155, by western blot analysis.
As presented in Fig. 3b, introduction of the miR-155
critically decreases the KRAS protein levels. Conversely,
no variations in KRAS protein levels were found when
the cells were transfected with a scrambled oligonucleo-
tide. Interestingly, modifications in the KRAS mRNA
amounts were detected in the cells transfected with the
miR-155 (Fig. 3c), thus indicating a role of miR-155 in
KRAS mRNA degradation.
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Several miRNAs regulate gene expression through base
pairing with the miRNA-recognizing elements (miR-RE)
in their mRNA target. To establish whether the direct
interaction between the miR-155 and KRAS mRNA is re-
sponsible for reduced expression of this protein, we intro-
duced downstream of the luciferase ORF, 485 bp (25-
510 bp) of the 3’-UTR of the KRAS mRNA. 293 cells were
transfected with the generated reporter vector and the
miR-155. Luciferase activity was much lower after miR-
155 transfection (Fig. 3d) than after transfection with the
scrambled oligonucleotide. The same reporter construct
of the previous experiments, but carrying mutations in
KRAS 3’ UTR at the miR-155 target site, was unresponsive
to the effects of miR-155 (Fig. 3d), proving that the modi-
fications of the target site of KRAS 3’ UTR are able to
block the function of this miRNA.
In agreement with the capacity of miR-155 to target
KRAS mRNA, the relative protein amounts are higher in
cbx7 KO MEFs in comparison with the WT (Fig. 3e).
According to the results obtained on cbx7 null MEFs,
the levels of KRAS protein were found downregulated in
A549 cells (human lung carcinoma line), overexpressing
the CBX7 protein (Fig. 4a), in which we found higher
miR-155 levels with respect to the same cells transfected
with the control vector (Fig. 4b).
miR-155 expression positively correlates with CBX7 in
human colon carcinoma
Then, we have evaluated miR-155 and the CBX7 gene
expression in colon carcinoma tissues by qRT-PCR. As
presented in Fig. 5, downregulation of both miR-155 and
CBX7 was observed in most of the carcinoma samples
in comparison with the normal colon mucosa. Linear re-
gression between CBX7 and miR-155 expression is also
reported (Fig. 5).
The direct correlation between CBX7 and miR-155 ex-
pression suggests that these genes are co-regulated in
human colon carcinomas. The presence of a mutated
KRAs status does seem to have any correlation with
miR-155 or CBX7 expression.
We have also analyzed KRAS expression at mRNA
level. These results are shown in the Additional file 1:
Figure S1. There is no significant correlation with CBX7
and miR-155 levels. It is likely that several other factors
act on KRAS mRNA levels in vivo, and maybe the effect
of miR-155 is exerted particularly at translation level.
Discussion
CBX7 has been already proposed as tumor suppressor
gene, since several studies have demonstrated that its ex-
pression is drastically downregulated in most of the ma-
lignant neoplasias [4], and the development of liver and
lung carcinomas in Cbx-7 null mice further supports the
CBX7 tumor suppressor activity [8]. Moreover, the res-
toration of CBX7 expression in carcinoma cells of differ-
ent origin results into a reduced growth rate [5, 7, 11,
33], blocking the cells in the G1 phase of the cell cycle.
Very recently, we have also reported that reestablish-
ment of CBX7 expression in two cell lines of human
lung carcinoma, in which it was undetectable, yields a
diminished proliferation and an improved apoptosis after
drug exposure [21]. However, CBX7 has been reported
to exert also oncogenic activity. Indeed, it was shown
that Cbx7 expression in mice lymphoid compartment
Table 1 List of the most studied and up-regulated miRNAs in WT MEFs (cbx7+/+) vs KO MEFs (cbx7-/-)
Unique Id Geom. Mean of intensities
(cbx7 +/+)




(cbx7 +/+vs cbx7 -/-)
Parametric
p-value
Mmu-mir-705 626.5 205.8 3.044 0.0062209
Mmu-mir-221 4233.9 2449.4 1.729 0.0035147
Mmu-mir-222 12079.2 6409 1.885 0.0017689
Mmu-mir-715 127.5 37.2 3.427 0.0016821
Mmu-mir-323 1775 633.6 2.801 0.0003329
Mmu-mir-155 2720.1 508.9 5.345 7.11e-05
Table 2 List of the most studied and down-regulated miRNAs in WT MEFs (cbx7+/+) vs KO MEFs (cbx7-/-)
Unique Id Geom. Mean of intensities: (cbx7 +/+) Geom. Mean of intensities: (cbx7 -/-) Ratio of geom
Means
(cbx7 +/+vs cbx7 -/-)
Parametric
p-value
Mmu-mir-137 113.9 687.8 0.166 0.0092591
Mmu-mir-181a-5p 1124.6 2092.2 0.538 0.0030335
Mmu-miR-719 18 186.1 0.097 0.0002231
Mmu-mir-199-5p 445.9 1481.1 0.301 0.0001483
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can promote T cell lymphomagenesis and, working to-
gether with c-Myc, produces aggressive B cell lymph-
omas by downregulating Ink4a/Arf locus [1]. Equally,
CBX7-positive patients affected by ovarian carcinoma
showed significantly shorter overall and progression-free
survival rates than those of the CBX7-negative patients.
Moreover, CBX7 knockdown significantly reduced cell
viability in two ovarian carcinoma cell lines compared to
the control cells, likely by the upregulation of tumor ne-
crosis factor-related apoptosis-inducing ligand (TRAIL)
[34]. Recently, we have reported that CBX7 regulates
several genes involved in tumor progression [12, 35]
such as E cadherin, cyclin E, SPP1 likely accounting for
the critical role of CBX7 in carcinogenesis.
In this study, we have envisaged the hypothesis that
CBX7 tumor suppressor or oncogenic role may be also
mediated by the regulation of miRNA expression since
the role of miRNAs in cancer development and progres-
sion has been frequently reported [36]. Consistently, we
previously demonstrated that CBX7 negatively regulates
the expression of miR-181 that has among its targets
CBX7, creating a synergistic loop that contributes to
breast cancer progression [11].
Then, we have studied the miRNA expression profile
of Cbx7 null MEFs versus the wt. Nine miRNAs were
found downregulated and twenty upregulated with a fold
change higher than 2 in the Cbx7 KO MEFs with respect
to WT counterparts. We first validated the results of the
array analyzing, by qRT-PCR, 5 deregulated miRNAs in
Cbx7 KO and WT MEFs.
On the basis of the opposite functions of CBX7, as onco-
gene and oncosuppressor, it was not surprising to find that
CBX7 was able to regulate in opposite sense miRNAs that
have recognized to have oncogenic functions, such as miR-
Fig. 1 Validation of MiRNA microarray data by qRT-PCR. qRT-PCR analysis of miR-181, miR-137, miR-199, miR-706, miR-719 and miR-155 in mouse
embryonic fibroblasts (MEFs) from Cbx7 -/- (KO) mice compared to wild type (WT), set equal to 1. qRT-PCR analysis was performed in triplicate and
reported values represent the mean ± SD. *, P < 0.05 **, P < 0.01 ***, P < 0.001 (t test)
Fig. 2 MiR-155 espression in MEFs derived from Cbx7 null and Cbx7 transgenic mice. a qRT-PCR analysis of miR-155 in MEFs derived from three
Cbx7 knock out lines (KO1, KO2, KO3) and control WT mice and b in MEFs derived from Cbx7 transgenic lines (TG1, TG2, TG3). qRT-PCR analyses
were performed in triplicate and reported values represent the mean ± SD. *, P < 0.05 (t test)
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Fig. 3 MiR-155 targets KRAS. a Schematic representation of KRAS 3’ UTR and relative position of the predicted miRNA- binding site. b Western
blot analysis of KRAS protein levels in HEK-293 cells transfected with miR-155 or a scrambled oligonucleotide. Actin expression was analyzed as
loading control. A representative experiment is shown. c qRT-PCR analyses of KRAS mRNA expression in HEK-293 cells transfected with miR-155 or
a scrambled oligonucleotide, normalized with G6PD. qRT-PCR analysis was performed in triplicate and reported values represent the mean ± SD.
d Relative luciferase activity in HEK-293 cells transiently transfected with 3’UTR-KRAS and 3’UTR-KRAS mutated in the miR-155 seed sequence along
with the miR 155 or with a scrambled oligonuclotide. e Western blot analysis of KRAS protein in MEFs Cbx7+/+ (WT) and Cbx7-/- (KO). Gapdh
expression was analyzed as loading control. **, P < 0.01 (t test)
Fig. 4 KRAS and miR-155 espression in A549 cell clones transfected with CBX7. aWestern blot analysis of KRAS protein in A549 cells expressing
CBX7 (A549-CBX7) versus A549 cells transfected with the empty vector (A549-CTR). Actin expression was analyzed as loading control. b qRT-PCR
analysis of miR-155 expression in A549-CBX7 cells versus A549-CTR cells, normalized with G6PD. qRT-PCR analysis was performed in triplicate and
reported values represent the mean ± SD. *, P < 0.05 (t test)
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199 (negatively regulated) and miR-155, miR-221 and miR-
222 (positively regulated). Equally, we observe that a poten-
tial oncosuppressor gene, such as miR-137, is regulated
negatively, whereas another one, such as miR-323, is regu-
lated positively. It is also not unlikely that the modulation
of these miRNAs might be specific of MEFs and that CBX7
could regulate the same miRNA positively or negatively de-
pending on the cellular context. Therefore, we retain that
the recent results evidencing a role of the loss of CBX7 ex-
pression in the progression of human colon cancer might
be also explained by the ability of CBX7 to modulate the
expression of several miRNAs.
Subsequently, we decided to focus on the miR-155
since it was one of the most downregulated miRNAs in
Cbx7 KO MEFs. Moreover, miR-155 is the most com-
monly miRNA overexpressed in malignancies among the
cancer-related miRNAs [28]. Bcl6, HDAC4, msh2, msh6,
mlh1 have been already identified as targets of miR-155
[26]. In liposarcoma casein kinase 1-α (CK1-α) is
targeted by miR-155, enhancing beta-catenin and cyclin
D1 [27]. In this study we have identified KRAS as target
of miR-155, since overexpression of miR-155 leads to a
drastic reduction of the KRAS mRNA and protein
levels indicating an effect of miR-155 also on KRAS
mRNA degradation. Consistently, higher KRAS pro-
tein levels were detected in Cbx7 null MEFs in com-
parison with the WT. The same result was achieved
when CBX7 expression was restored in lung carcin-
oma cells. However, the analysis of KRAS specific
mRNA does not reveal any correlation with miR-155
and CBX7 expression. Maybe this correlation is
present at protein levels, and we can also hypothesize
that the regulation of KRAS by miR-155 is specific of
some tissues depending on the cellular context.
It is likely that the targeting of KRAS may have a role
in the anti-apoptotic activity of miR-155 observed in
monocytic differentiation where miR-155 seems to have
as targets other anti-apoptotic factors such as RPS6KA3,
Fig. 5 Correlation between CBX7 expression and miR-155 expression in colon carcinoma tissues. qRT-PCR analysis of CBX7 and miR-155 expression
in colorectal carcinoma (CRC) compared with normal tissue. qRT-PCR analysis was performed in triplicate and reported values represent the mean
± SD. The fold change indicates the relative change in expression levels between tumors samples and normal samples, assuming that the value
of each normal sample is equal to 1. Linear regressions of CBX7 versus mir-155 is shown. KRAS mutation status of the colon cancer samples are
indicated at the bottom of the figure
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SGK3, and RHEB. It is likely that this anti-apoptotic ac-
tivity may be important for the growth of MEFs, also as-
sociated to the increased mR-221 and miR-222 levels
that are able to target p27 [37], a critical negative regula-
tor of the cell cycle.
Interestingly, CBX7 seems to positively regulate miR-
323: this can account for the reduced miR-323 expres-
sion in prostate cancer where CBX7 is drastically down-
regulated [38] and miR-323 has a tumor suppressor
activity by targeting AdipoRI [39].
Conclusion
In conclusion, these studies demonstrate that CBX7 is
able to positively regulate miR-155 and identify KRAS as
one of the target genes of this miRNA likely accounting
for the anti-apoptotic activity ascribed to miR-155 in
some tissue context.
Additional file
Additional file 1: Figure S1. qRT-PCR analysis of KRAS expression in
colorectal carcinoma (CRC) compared with normal tissue. qRT-PCR
analysis was performed in triplicate and reported values represent the
mean ± SD. The fold change indicates the relative change in expression
levels between tumors samples and normal samples, assuming that the
value of each normal sample is equal to 1. (TIF 757 kb)
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